Related Experiment Video
Updated: Aug 5, 2026

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition
Published on: September 20, 2019
Efficacy of Nutrilite® All Plant Protein in Postprandial Glycemic Control: A Non-randomized, Controlled, Crossover
Madhusudan Channappa1, Swati Shukla2, Aparna Damle2
1Research and Development, NRR Hospital, Bengaluru, IND.
None:
Glucose balance is essential for life and health. It's regulated by organs that absorb glucose after eating and by the liver that produces glucose during fasting. This study aimed to investigate the acute effect of Nutrilite® All Plant Protein (APP), administered as a preload in 250 mL spiced buttermilk, on glycemic response to a standardized 75 g oral glucose load in individuals with compromised blood glucose levels. The impact of APP, a plant-based dietary protein formulation, was assessed using a non-randomized, fixed-sequence, controlled crossover design to evaluate its potential as a nutritional intervention to improve glycemic response. Fourteen participants were enrolled in the study. Efficacy analyses were conducted in the complete paired efficacy population, defined as participants with usable paired glucose measurements at both intervention visits and all predefined time points (n = 10). Blood glucose spikes were better regulated with APP preload at almost all time points compared to the reference product (glucose). In this acute oral glucose tolerance test (OGTT)-based setting, participants maintained glucose values within the normoglycemic range for a longer duration after the APP preload condition than after the glucose-only reference condition. In the complete paired efficacy population (n = 10), the average incremental area under the curve (iAUC) for the reference product was 3049.5 ± 1290.45. In contrast, the average iAUC for APP combined with the reference product was 700.5 ± 688.74, representing a 78% reduction. This decrease in iAUC was statistically significant (p < 0.005). The significant reduction in iAUC suggests that APP may blunt acute glycemic excursions after a 75 g oral glucose challenge. These findings should not be directly extrapolated to mixed-meal settings without additional vehicle-controlled and meal-based studies. Furthermore, the findings should be interpreted as an acute reshaping of the OGTT glucose response curve rather than as evidence of uniformly improved glycemic control throughout the full 120-minute period.
Related Concept Videos
Bioavailability Study Design: Healthy Subjects Versus Patients
Oral Hypoglycemic Agents: Glinides
Dipeptidyl Peptidase 4 Inhibitors
Glucagon-like Receptor Agonists
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
Bioavailability Study Design: Single Versus Multiple Dose Studies